Study of AT03-65 for advanced CLDN6-positive solid tumors
Part of Cancer clinical trials.
This early-phase trial tests an investigational drug (AT03-65) for people with advanced solid tumors that have a certain protein called CLDN6. The goal is to see if the drug is safe and if it might help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor that has not responded to standard treatments, or you cannot take them.
- Your tumor has a specific protein called CLDN6 (claudin-6) that can be seen with a biopsy.
- You are well enough to be up and about (ECOG score 0 or 1).
- You have at least a 3-month life expectancy.
- You are willing to use highly effective birth control for 6 months after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TJ037130 for people with advanced solid tumors that have a specific protein called Claudin 6 (CLDN6) on their cells. The goal is to see if the drug is safe and works against the cancer.
This trial tests a new drug called AT-1965 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can shrink tumors.
This trial tests a new drug called NBL-028 in people with advanced solid tumors that have a specific protein (CLDN6). It is for those who have already tried standard treatments. The goal is to see how safe and effective the drug is.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.